Excommunicado

Excommunicado | Joined since 2019-11-28

Investing Experience -
Risk Profile -

Followers

0

Following

0

Blog Posts

0

Threads

5

Blogs

Threads

Portfolio

Follower

Following

Summary
Total comments
5
Past 30 days
0
Past 7 days
0
Today
0

User Comments
Stock

2021-06-23 14:41 | Report Abuse

Shouldn't be a problem with good fundamental stock as we might be heading towards recovery. If big selling didn't manage to push the price down too much, you have found a nice support. Bolinger bands are showing reduced volatity. RSI about 50s. The price might head up or down depending on the whole economic, recovery and political situation. Reminds me of dodgecoin at 0.05 before going up to 0.7. The only risk of it is the delta plus variant which might hinder all the efforts of vaccination and MCO.

Stock

2020-06-14 07:57 | Report Abuse

Third phase of trial is a human trial and will take a year for the vaccine to validate its effectiveness. The major problem with coronavirus is that it mutates fast

Stock

2020-02-23 06:53 | Report Abuse

No mikecyc, not at all.

Stock

2020-02-22 22:43 | Report Abuse

Maybe it's not very nice to call names. I3 is a great platform to share thoughts and knowledge but not showing aggression to others.

Still remain bullish with t7 with the current contracts and that new aerospace sector. T7 is also forming a nice wedge and golden cross, even though it might not mean anything to most people.

Stock

2019-12-02 23:10 | Report Abuse

Being the person who is directly involved in Sapien 3 valve by Edwards Lifesciences , it's the only valve in the world that has direct competition with the valve by medtronic. The Asian penetration of this valve is still at the beginning stage, but soon we will see an increase in the usage of sapien 3. The only downside is the vale costs about 100k. However, it's been widely used in European countries. What I can see is the revenue for it will continue to grow in near future because of the new research paper on the usage of the valve named Partner III trial. Hence, it's quite a safe assumption that the revenue will keep growing from the medical side.